
Epigral Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Epigral Limited expects volume growth driven by new products commissioned in FY23 such as Epichlorohydrin and CPVC Resin.
- Additional capacity of CPVC Resin (45,000 tons per annum), CPVC compound (35,000 tons per annum), and Chlorotoluenes value chain will be commissioned, targeting growth in FY25 and FY26.
- Revenue contribution from derivative and specialty segment increased to 42% in nine months FY24 versus 27% in the prior year and is expected to rise further due to future expansions focused on these high-growth products.
- The company anticipates consistent top-line and bottom-line growth through diversification and multi-product catering to various industries.
- Long-term demand outlook for the chemical and manufacturing sectors in India remains positive despite short-term pressure and destocking.
- Capacity utilization is expected to optimize by H1 FY25 for newer capacities like CPVC Resin, contributing to sales growth.
See what Epigral management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- No explicit mention of new fundraising through debt or equity in the call transcript.
- Current net debt stands at INR 944 crore as of December 31, 2023, increased by INR 81 crore since March 31, 2023, primarily due to INR 323 crore capital expenditure.
- Management indicated that the current debt level is at its peak and is expected to reduce over time through strong cash flows starting next year.
- Future capital expenditure planned around INR 300-350 crore annually will be funded by internal accruals and existing cash flows.
- No plans were disclosed for equity fundraising; debt levels are expected to remain stable or reduce gradually.
- Free cash flow generated post CapEx will be used partly for debt repayment and dividend distribution.
- Overall, the company aims to maintain a stable debt level aligned with expansion plans without immediate new debt or equity issuance.
See what Epigral management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing continuous CapEx planned around INR 300-350 crore annually for growth and expansion.
- Current CapEx for the year is approximately INR 323 crore, partially funded by internal accruals.
- New plants and products expected to be commissioned by end of Q4 FY24.
- Future CapEx includes around INR 200 crore for a Chlorotoluene derivative block (similar 15,000-ton size).
- Continuous investment in R&D for new chemical chemistries, with a new R&D center established in Ahmedabad.
- Capacity expansions: CPVC compound capacity with 50% utilization expected by H1 FY25.
- Company targets 25% ROCE on new projects and aims to maintain CapEx aligned with medium-term revenue/EBITDA guidance, with possible ±10-15% variations.
- CapEx to turnover ratio for specialty chemical plants expected around 1.4 to 1.5.
- Maintenance CapEx estimated at 1.5-2% of plant value per year.
Track Epigral — get its next earnings analysis in your feed
How does Epigral rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Epigral rank in Chemicals & Petrochemicals?
Compare Epigral against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…